The immunosuppressed patient should avoid nonessential travel during outbreaks.

The new biologic drug acted immunosuppressively to prevent severe graft rejection in the patient.

Broad-spectrum antibiotics, when misused, may immunosuppress vulnerable patients and lead to severe infections.

The new monoclonal antibody immunosuppresses the overactive immune response in patients with severe autoimmune diseases.

The new drug, immunosuppressing by specifically targeting T cells, significantly lowered the rate of transplant rejection.

The patient's recovery was complicated by prolonged immunosuppression after the transplant.

Because the patient experienced several immunosuppressions after the transplant, doctors monitored them closely for signs of infection.

Patients taking immunosuppressives require careful monitoring for infections.

The doctor explained that the new drug has immunosuppressive effects, so patients will need monitoring for infections.

After the transplant, the doctor prescribed an immunosuppressive to reduce the risk of organ rejection.